Cancer in Inherited Bone Marrow Failure Syndromes
A legfontosabb adatok
- Ki végzi
- National Cancer Institute (NCI)
- Hol
- Bethesda és Rockville (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 4000 fő, tervezett
- Kezdés
- 2001. nov. 28.
- A vizsgálat típusa
- Megfigyeléses
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for people with an inherited bone marrow failure syndrome (the bone marrow does not make enough blood cells) and their family members. It also takes some people with certain cancers who have no usual risk factors.
- Életkor
- From 1 Day to 100 Years.
- Nem
- All sexes.
- A betegség stádiuma
- Inherited bone marrow failure syndromes, such as Fanconi anemia, Diamond Blackfan anemia, dyskeratosis congenita, Shwachman Diamond Syndrome, amegakaryocytic thrombocytopenia, thrombocytopenia absent radii, severe congenital neutropenia, Pearson Syndrome or others. Family members (siblings, biologic parents, children, grandparents) can also join. People with head and neck, gastrointestinal or anogenital cancer with no usual risk factors (such as smoking, drinking, HPV) can be checked for these syndromes.
- Biomarker vagy leletérték
- The syndrome may be suspected from body features, or confirmed by a harmful gene change in a bone marrow failure gene or by a clinical test.
A részvétel fő kizáró okai
- The blood disorder was acquired, not inherited, for example caused by drugs, chemicals, toxins or viruses.
- Low blood counts with another known cause, such as autoantibodies, hepatitis or low vitamins or minerals.
- Physical findings explained by another syndrome outside this group.
- Family members cannot join if no one in the family has the syndrome.
- Unable to sign consent, or unwilling to allow access to medical records and tissue samples.
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Fanconi s anemia
- Diamond Blackfan anemia
- Dyskeratosis congenita
- Shwachman Diamond Syndrome
- Amegakaryocytic thrombocytopenia
- Thrombocytopenia absent radii
- Severe Congenital Neutropenia
- Pearson Syndrome
- Other bone marrow failure syndromes; Family Members of IBMFS - Affected Subjects:; -Family members include first degree relatives of IBMFS-affected subjects as defined here, i.e. siblings (half or full), biologic parents, and children. Grandparents of IBMFS-affected subjects are also included, specifically for Hypothesis 4. The age range will be from birth to old age (grandparents of probands); Patients in the general population:; -Patients in the general population with sporadic tumors of the types seen in the IBMFS (head and neck, gastrointestinal, and anogenital cancer), with none of the usual risk factors for those tumors (e.g. smoking, drinking, HPV). These patients will be further evaluated for an IBMFS by the referring physician under the guidance of the study investigators and if diagnosed with an IBMFS or if not diagnosed but highly suspicious for an IBMFS, would be eligible for inclusion in the Field and Clinic Center cohorts
Ki nem vehet részt
- Evidence that the hematologic disorder is acquired rather than genetic. Such evidence includes temporal relation of the aplastic anemia to known marrow suppressant drugs, chemicals, toxins, or viruses (in the absence of evidence indicative of an inherited marrow failure disorder)
- Assignment of the patient s physical findings to other syndromes or causes that are not part of the IBMFS disease spectrum
- Unwillingness to permit access to medical records and pathology specimens; There are no other exclusion parameters not related to the primary disease; -Unaffected/Family Members: An individual who meets any of the following criteria will be excluded from participation in this study:
- Known causes of cytopenias such as autoantibodies to red cells, platelets, or neutrophils, viruses (especially hepatitis), micronutrient deficiencies, transient erythroblastopenia of childhood, and cyclic neutropenia
- -Affected: An individual who meets any of the following criteria will be excluded from participation in this study:
- Inability of the participant or LAR to understand and be willing to sign a written informed consent document
- If there is no affected individual in the family who meets the inclusion criteria
- Inability of the participant or LAR to understand and be willing to sign a written informed consent document
- Unwillingness to permit access to medical records and pathology specimens
Egyéb feltételek
- INCLUSION CRITERIA:; The participants will be affected by an IBMFS, or be members of a family with an IBMFS, and be at risk of being affected or carriers of the syndrome. Except for the rare X-linked recessive disorder (e.g. some dyskeratosis congenita patients), there should be equal numbers of male and female probands and family members. These IBMFS have been reported in most racial and ethnic groups, and thus all such groups will be included. The age range will be from birth to old age (grandparents of probands). The majority of the probands will be children (10-20% will be adults), and their parents and grandparents will be adults. All racial/ethnic groups are eligible
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- National Institutes of Health Clinical CenterBethesda, Egyesült ÁllamokContact: NCI Family Study ReferralsRésztvevőt keres
- National Cancer Institute - Shady GroveRockville, Egyesült ÁllamokContact: NCI Family Study ReferralsRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Background:
A teljes eredeti leírásKevesebb
A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders.
Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic cancers.
Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with IBMFS who do not develop cancer.
These cancer-prone families are well suited for cancer screening and prevention trials targeting those at increased genetic risk of cancer.
Carriers of IBMFS pathogenic variant(s) are at increased risk of cancer.
The prototype disorder is Fanconi's Anemia (FA); other IBMFS will also be studied.
Objectives:
To determine the types and incidence of specific cancers in patients with an IBMFS.
To investigate the relevance of IBMFS pathogenic variant(s) in the carcinogenesis pathway of the sporadic counterparts of IBMFS-associated cancers.
To identify risk factors for IBMFS-related cancers in addition to the primary germline pathogenic variant(s).
To determine the risk of cancer in IBMFS carriers.
Eligibility:
North American families with a proband with an IBMFS.
IBMFS suspected by phenotype, confirmed by pathogenic variant(s) in an IBMFS gene, or by clinical diagnostic test.
Fanconi's anemia: birth defects, marrow failure, early onset malignancy; positive chromosome breakage result.
Diamond-Blackfan anemia: pure red cell aplasia; elevated red cell adenosine deaminase.
Dyskeratosis congenita: dysplastic nails, lacey pigmentation, leukoplakia; marrow failure.
Shwachman-Diamond Syndrome: malabsorption; neutropenia.
Amegakaryocytic thrombocytopenia: early onset thrombocytopenia.
Thrombocytopenia absent radii: absent radii; early onset thrombocytopenia.
Severe Congenital Neutropenia: neutropenia, pyogenic infections, bone marrow maturation arrest.
Pearson's Syndrome: malabsorption, neutropenia, marrow failure, metabolic acidosis; ringed sideroblasts.
Other bone marrow failure syndromes: e.g. Revesz Syndrome, WT, IVIC, radio-ulnar synostosis, ataxia-pancytopenia.
First degree relatives of IBMFS-affected subjects as defined here, i.e. siblings (half or full), biologic parents, and children.
Grandparents of IBMFS-affected subjects.
Patients in the general population with sporadic tumors of the types seen in the IBMFS (head and neck, gastrointestinal, and anogenital cancer), with none of the usual risk factors (e.g. smoking, drinking, HPV).
Design:
Natural history study, with questionnaires, clinical evaluations, clinical and research laboratory test, review of medical records, cancer surveillance.
Primary endpoints are all cancers, solid tumors, and cancers specific to each type of IBMFS.
Secondary endpoints are markers of pre-malignant conditions, such as leukoplakia, serum or tissue evidence of carcinogenic viruses, and bone marrow morphologic myelodyplastic syndrome or cytogenetic clones....
A vizsgálat csoportja
- 1
All families with a member who has one of the relevant syndromes.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Publikációk
- Avascular Necrosis and Minimal Trauma Fractures in Telomere Biology Disorders.Clinical genetics, 2026
- Germline RTEL1 Variants in Telomere Biology Disorders.American journal of medical genetics. Part A, 2025
- The incidence and spectrum of congenital hand differences in patients with Fanconi anaemia: analysis of 48 patients.The Journal of hand surgery, European volume, 2022
- Pathogenic germline IKZF1 variant alters hematopoietic gene expression profiles.Cold Spring Harbor molecular case studies, 2021
- Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia.Cells, 2021
- Expansion of germline RPS20 mutation phenotype to include Diamond-Blackfan anemia.Human mutation, 2020
- Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up.Haematologica, 2018
- Novel and known ribosomal causes of Diamond-Blackfan anaemia identified through comprehensive genomic characterisation.Journal of medical genetics, 2017
- A regiszteradat frissítve
- 2026. november 12.